Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Agios Pharmaceuticals (AGIO) Receivables - Other (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Receivables - Other for 14 consecutive years, with $16.1 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables - Other rose 382.42% year-over-year to $16.1 million; the TTM value through Mar 2026 reached $16.1 million, up 382.42%, while the annual FY2025 figure was $10.6 million, 157.41% up from the prior year.
  • Receivables - Other hit $16.1 million in Q1 2026 for Agios Pharmaceuticals, up from $10.6 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $16.1 million in Q1 2026 and bottomed at $540000.0 in Q1 2022.
  • Average Receivables - Other over 5 years is $4.0 million, with a median of $3.1 million recorded in 2024.
  • Year-over-year, Receivables - Other plummeted 80.35% in 2022 and then soared 382.42% in 2026.
  • Agios Pharmaceuticals' Receivables - Other stood at $2.2 million in 2022, then grew by 27.38% to $2.8 million in 2023, then soared by 46.23% to $4.1 million in 2024, then soared by 157.41% to $10.6 million in 2025, then surged by 52.52% to $16.1 million in 2026.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $16.1 million, $10.6 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.